Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish medtech company, NOLabs has achieved another important milestone in the development of a new line of products for wounds infected by the MRSA-bacteria, which is particularly troublesome in hospital-acquired infections due to its resistance to several traditional antibiotics.
Subscribe to our email newsletter
In experiments performed at the Malmoe University Hospital in Sweden, researchers showed that NOLabs’ technology has a promising ability to kill a wide range of pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Goran Beijer, CEO of NOLabs, said: “The anti-microbial effect of NO will be key in several products that will prevent or treat infection depending on dosing. We are now accelerating our development program and expect to have the first products on the market during 2008.”